Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma

Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer

(2015) Helen M. Coley et al.   Oncotarget

Conflicting Roles of Molecules in Hepatocarcinogenesis: Paradigm or Paradox

(2012) Gen-Sheng Feng   CANCER CELL

Inhibition of hedgehog signaling attenuates carcinogenesisin vitroand increases necrosis of cholangiocellular carcinoma

(2012) Mona El Khatib et al.   HEPATOLOGY

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo

(2011) Xianzhe Liu et al.   ANTI-CANCER DRUGS

Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened Antagonists

(2011) C. Metcalfe et al.   CANCER RESEARCH

From Plk1 to Plk5

(2011) Guillermo de Cárcer et al.   CELL CYCLE

Myofibroblast-derived PDGF-BB promotes hedgehog survival signaling in cholangiocarcinoma cells

(2011) Christian D. Fingas et al.   HEPATOLOGY

Hedgehog Inhibition Promotes a Switch from Type II to Type I Cell Death Receptor Signaling in Cancer Cells

(2011) Satoshi Kurita et al.   PLoS One

A smac mimetic reduces TNF Related Apoptosis Inducing Ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells

(2010) Christian D. Fingas et al.   HEPATOLOGY

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

(2010) Klaus Strebhardt   NATURE REVIEWS DRUG DISCOVERY

GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis

(2010) S Kurita et al.   ONCOGENE

Prognostic Assessment of Three Single-Nucleotide Polymorphisms (GNB3825C>T,BCL2-938C>A,MCL1-386C>G) in Extrahepatic Cholangiocarcinoma

(2009) Christian Dominik Fingas et al.   CANCER INVESTIGATION

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Mcl-1 Degradation during Hepatocyte Lipoapoptosis

(2009) Howard C. Masuoka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology

(2009) P. Schoffski   ONCOLOGIST

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

(2009) R. L. Yauch et al.   SCIENCE

Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment

(2008) Boris Blechacz et al.   HEPATOLOGY

Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma

(2008) Yan-Bin Feng et al.   INTERNATIONAL JOURNAL OF CANCER